{
    "symbol": "CATX",
    "quarter": 1,
    "year": 2023,
    "date": "2022-11-10 18:55:05",
    "content": " We will begin today\u00e2\u0080\u0099s call with Lori Woods, Isoray\u00e2\u0080\u0099s Chief Executive Officer; and Thijs Spoor, Chief Executive Officer of Viewpoint Molecular Targeting; and then Jonathan Hunt, Isoray's Chief Financial Officer will discuss the fiscal first quarter 2023 financial results. Total other brachytherapy revenue only declined 7% versus the first quarter of fiscal '22 as sales to treat brain cancers, which includes sales to GT Medical Technologies increased 15% year-over-year despite the supply disruption. First quarter gross profit dollars of $414,000 decreased 60% when compared to the same period last year, total operating expenses, consisting of research and development, sales and marketing and general and administrative increased to $4.6 million versus $3.3 million in the first quarter of 2022."
}